Weight loss medications have come a long way. For years, people struggling with stubborn weight had limited options – restrictive diets, exhausting exercise plans, or medications with uncomfortable side effects and modest results. That’s changed dramatically.
Today, two medications are dominating the conversation: semaglutide (brand names Ozempic and Wegovy) and tirzepatide (brand names Mounjaro and Zepbound). Both work. Both are safe when prescribed appropriately. But when it comes to overall weight loss results, tirzepatide tends to deliver greater reductions for most people, and the clinical data backs that up. That said, the best choice for you depends on your health history, your body’s response, and your provider’s recommendations.
Let’s break down what each medication actually does, how they compare, and what you should realistically expect.
Both semaglutide and tirzepatide belong to a class of drugs that mimic naturally occurring hormones involved in hunger and blood sugar regulation. But they don’t work in exactly the same way.
Semaglutide is a GLP-1 receptor agonist. GLP-1 is a hormone your gut releases after eating. It signals your brain that you’re full, slows how quickly food leaves your stomach, and helps regulate insulin. When you take semaglutide, you’re essentially amplifying that “I’m satisfied” signal, which means you eat less without feeling deprived.
Tirzepatide does all of that, and more. It activates two receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone that plays a role in fat storage and energy metabolism. By targeting both pathways, tirzepatide gives your body a stronger and more comprehensive signal to reduce appetite, improve insulin sensitivity, and burn stored fat more efficiently. Think of it like using two levers instead of one.
The clinical trial data is compelling, and it’s worth knowing about before you make any decisions.
In the SURMOUNT-1 trial, participants taking the highest dose of tirzepatide (15 mg) lost an average of 22.5% of their body weight over 72 weeks. For someone weighing 250 pounds, that’s roughly 56 pounds.
In the STEP 1 trial for semaglutide, participants lost an average of 14.9% of body weight over 68 weeks – still a meaningful and life-changing result, but notably less than tirzepatide’s top-line numbers.
A 2023 real-world analysis published in JAMA Internal Medicine confirmed what the trials suggested: people taking tirzepatide lost more weight on average than those taking semaglutide, across multiple time points and dose levels.
To put it simply:
Tirzepatide users tend to lose more total weight
Results with tirzepatide appear faster in the first few months
Both medications significantly outperform lifestyle intervention alone
Individual results still vary – genetics, starting weight, diet, and consistency all matter
Both medications share a similar side effect profile since they work on overlapping hormone pathways. The most commonly reported issues include:
Nausea (especially in the first few weeks as your dose increases)
Constipation or diarrhea
Fatigue
Reduced appetite (which is also the goal, but can feel uncomfortable at first)
These side effects are usually mild and tend to improve after the first month as your body adjusts. Starting at a low dose and gradually increasing – which is standard protocol – helps most people tolerate treatment well.
There’s no strong evidence that one medication causes significantly more side effects than the other at comparable doses. Some patients actually report fewer GI complaints with tirzepatide, though this isn’t universal. The bottom line: both are generally well-tolerated when managed by an experienced provider.
It’s important to note that neither medication is appropriate for people with a personal or family history of medullary thyroid cancer or MEN2 syndrome. A thorough medical evaluation before starting either treatment is non-negotiable.
Both medications can be expensive without insurance coverage, often costing $900–$1,300 per month at retail. Coverage varies widely depending on your plan. Wegovy (semaglutide for weight loss) has broader insurance approval than Zepbound (tirzepatide for weight loss), which is newer and still working its way through coverage approvals.
Compounded versions of both medications have become widely available through medical practices, and while they can significantly reduce cost, quality and dosing accuracy vary. This is exactly the kind of thing to discuss directly with your provider – not something to navigate alone through online pharmacies.
Here’s the honest answer: if you’re a candidate for either medication, tirzepatide currently shows stronger weight loss outcomes in clinical data and real-world use. For patients whose primary goal is maximum weight reduction, it’s often the first recommendation.
But semaglutide is far from a consolation prize. There are several reasons your provider might recommend it instead:
You’ve already had a positive response to semaglutide in the past
Insurance coverage makes semaglutide significantly more affordable for you
Your health history or other medications make tirzepatide a less suitable option
Availability in your area – supply chain issues have affected both medications at different times
The reality is that losing 15% of your body weight with semaglutide is still a profound health outcome. For many people, it’s life-changing. Reducing that number to “only” 15% undersells what that actually means – lower blood pressure, improved cholesterol, reduced joint pain, better sleep, and a meaningfully different quality of life.
At ellevateMD, we don’t believe in one-size-fits-all protocols. Dr. Ann Jayaram and our team take the time to understand your full health picture – your metabolic history, your goals, any medications you’re currently taking, and what success realistically looks like for you.
Weight loss medication is a tool. A powerful one. But it works best when it’s part of a thoughtful plan that includes nutritional support, accountability, and ongoing monitoring. We adjust doses based on how you’re feeling and how your body responds – not on a generic schedule.
Tirzepatide and semaglutide are both genuinely effective, well-studied medications for weight loss. Tirzepatide has the edge when it comes to average pounds lost. Semaglutide has a longer track record and is often more accessible through insurance. Neither is the right choice without a proper medical evaluation.
What matters most isn’t which medication has the better headline number – it’s finding the approach that fits your body, your lifestyle, and your long-term health. That conversation starts with a provider who actually knows you.
If you’re ready to explore whether tirzepatide or semaglutide is right for you, we’d love to talk.
Dr. Ann Jayaram is a board-certified oculoplastic surgeon and the founder of ellevateMD. She is passionate about whole-body wellness and helping patients feel confident at every stage of life.
About the Author
Dr. Ann Jayaram
As a surgeon, my highest priority is to help each patient achieve a result that feels true to who they are, beautiful, but natural and uniquely their own.
April 20, 2026